



Advancing Research. Improving Lives.™

TO: ALL PRINCIPAL INVESTIGATORS, NURSES AND DATA MANAGERS

FROM: NRG-DT001 Study Chair
Meng Welliver, MD, PhD

DATE: Wednesday, September 7, 2022

RE: PROTOCOL NRG-DT001 – COHORT B CLOSURE

Cohort B (abdomen/pelvis/retroperitoneum) of NRG-DT001, “A Phase IB Trial of Neoadjuvant AMG 232 (KRT-232) Concurrent with Preoperative Radiotherapy in Wild-Type p53 Soft Tissue Sarcoma (STS),” is permanently closed to accrual as of **5 PM ET Wednesday, September 7, 2022**, because the accrual record indicates there is no feasible pathway to achieve the protocol objective in a timely manner, as broadcasted on Wednesday, August 31, 2022.

Reminders:

- All patients registered to Step 1 registration by 5 PM ET Wednesday, September 7, 2022 will be permitted to proceed to the Step 2 registration.
- Data collection and site IRB renewal for closed studies must continue until the study is terminated.
- Sites that do not have active patients on treatment must follow PMB’s guidelines for drug accountability and destruction of unused drug. See protocol section 9.2 for further details.

Please distribute this information to the appropriate personnel at participating affiliate institutions.